Cytomegalovirus hepatitis
Conditions
Interventions
Basic treatment group:Altomoland
Spleen aminopeptide treatment group:Spleen aminopeptide
Basic treatment + spleen aminopeptide treatment group:Altomoland + spleen aminopeptide
Healthy control (not randomization):no
Sponsors
Department of Gastroenterology, Affiliated Children's Hospital, Nanjing Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) It is planned to be included in the children with CMV hepatitis admitted to the Department of Gastroenterology, Children's Hospital of Nanjing Medical University from January 2019 to December 2020. They were randomly divided into basic treatment group, spleen amino peptide treatment group, basic treatment + spleen amino peptide. Treatment group, 30 people in each group; (2) The above-mentioned groups of children with atomolan + compound glycyrrhizin basic treatment or combined with spleen aminopeptide treatment; (3) basic treatment: combination of atomolan and glycyrrhizin, treatment course for 1 month; spleen amino peptide oral lyophilized powder dissolved in 10ml cold water after oral administration, >1 year old children 2mg / time, 1 time / d, Oral before going to bed at night; = 1 year old children 2mg / time, 1 time / every other day, oral before going to bed at night, 2 weeks after going home, the total course of treatment in January; (4) The first and 30th days of treatment were evaluated; (5) Aged 6-14 years old; (6) There was no significant difference in age and gender between the children in the experimental group and the healthy group. CMV hepatitis inclusion criteria: according to the Chinese Medical Association Pediatrics Branch infection CHEN infection CMV infection diagnosis program (Chinese Journal of Pediatrics, 1999, 37: 441), and other hepatitis caused by other common hepatitis virus infection in infancy, that is, the following conditions: (1) Peripheral blood or urine CMV-DNA and CMV-IgM positive, Toxoplasma antibody, rubella virus antibody, herpes virus antibody, EB virus, hepatitis A, hepatitis B, hepatitis C, hepatitis D and pent Hepatitis B antibody test was negative; (2) Peripheral blood ALT and bound bilirubin (DB) were higher than normal.
Exclusion criteria
Exclusion criteria: 1) have contraindications to the use of spleen aminoglycans; 2) exclude primary immunodeficiency diseases, congenital heart disease, rickets, malnutrition and other diseases, as well as children who have been treated with other immunopotentiators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alanine aminotransferase;Bilirubin;serum IL-17, IL-23;Peripheral blood lymphocytes IL-17R, ROR?t, IL-10, IL-1ß and TNF-a mRNA;IL-17R, ROR?t mRNA expression and supernatant IL-17 levels in Th17 cells; | — |
Countries
China
Contacts
Public ContactYang Hui
Department of Gastroenterology, Affiliated Children 's Hospital, Nanjing Medical University
Outcome results
None listed